TRT for Men With Type 2 Diabetes & Metabolic Syndrome: What the 2026 Research Says

For decades, the relationship between low testosterone, type 2 diabetes, and metabolic syndrome was treated as an unfortunate coincidence. Men with poorly controlled blood sugar happened to have low T. Men with expanding waistlines happened to feel fatigued and depressed. The connections were observed, but rarely acted upon.

That changed dramatically between 2023 and 2026. A convergence of landmark clinical trials, FDA regulatory shifts, and evolving endocrine guidelines has established what many clinicians long suspected: hypogonadism and metabolic dysfunction are not parallel problems — they are mechanistically intertwined, and treating one often improves the other.

In February 2025, the FDA removed the cardiovascular black-box warning from testosterone products following the TRAVERSE trial data. And in 2024–2026, multiple large-scale studies demonstrated that testosterone replacement therapy can significantly improve insulin sensitivity, HbA1c, and body composition in hypogonadal men with type 2 diabetes. This article breaks down the science, the trials, and what it means for patients today.

The Bidirectional Relationship: Low T and Metabolic Syndrome

Understanding why TRT can help diabetic men starts with understanding the vicious cycle that connects low testosterone and metabolic dysfunction. This isn't a one-way street — it's a self-reinforcing loop:

How Obesity Drives Down Testosterone

Adipose tissue (body fat) is highly active endocrine tissue. It contains high concentrations of aromatase, the enzyme that converts testosterone to estradiol. As visceral fat accumulates, aromatase activity increases, pulling testosterone out of the androgen pathway and converting it to estrogen. This elevated estradiol then suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, reducing LH secretion and further suppressing testicular testosterone production.

Additionally, obesity-related insulin resistance drives SHBG levels down. While low SHBG can temporarily increase free testosterone, the net effect of the hyperinsulinemic state is a progressive decline in total testosterone production. A 2010 meta-analysis by Corona et al. in the Journal of Sexual Medicine (n = 3,825 men) found that men with metabolic syndrome had testosterone levels averaging 2.64 nmol/L (76 ng/dL) lower than metabolically healthy controls — a clinically significant deficit.

How Low Testosterone Worsens Metabolic Dysfunction

The cycle then feeds back. Low testosterone itself promotes:

• Increased visceral fat deposition: Testosterone is a primary regulator of fat distribution in men. Low T shifts fat storage from peripheral (subcutaneous) to central (visceral), which is the most metabolically dangerous phenotype.
• Reduced muscle mass and metabolic rate: Skeletal muscle is the body's largest insulin-sensitive tissue. As testosterone drops, muscle mass decreases, reducing glucose disposal capacity and worsening insulin resistance.
• Systemic inflammation: Low testosterone is associated with elevated inflammatory cytokines (IL-6, TNF-α, CRP), which directly impair insulin receptor signaling.
• Reduced mitochondrial function: Testosterone supports mitochondrial biogenesis in skeletal muscle. Low T means less efficient fatty acid oxidation and glucose metabolism at the cellular level.
• Fatigue and reduced physical activity: Perhaps the most underappreciated factor — men with low T exercise less, move less, and have less energy to prepare healthy meals, compounding every metabolic variable listed above.

The result is a downward spiral: obesity drives testosterone down, and low testosterone drives metabolic dysfunction up. Understanding this bidirectional mechanism is essential because it explains why breaking the cycle — even at just one point — can produce cascading improvements.

The FDA's Cardiovascular Reversal: What Changed in 2025

For years, the single biggest barrier to prescribing TRT to metabolically complex patients was the 2015 FDA-mandated cardiovascular warning label on testosterone products. This label — based on two flawed observational studies (Finkle et al. 2014 and Vigen et al. 2013, the latter later partially retracted) — cast a shadow over TRT that discouraged cardiologists and endocrinologists from treating hypogonadal men with cardiovascular risk factors, including type 2 diabetes.

Then came the TRAVERSE Trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and efficacy ResponSE in hypogonadal men). Published in the New England Journal of Medicine in 2023, TRAVERSE enrolled 5,246 men aged 45–80 with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. After a mean follow-up of 33 months:

• The primary endpoint — a composite of cardiovascular death, nonfatal MI, and nonfatal stroke — occurred in 7.0% of the testosterone group vs. 7.3% of the placebo group (HR 0.96, 95% CI 0.78–1.17). No increase in cardiovascular events whatsoever.
• In February 2025, based on this and subsequent confirmatory data, the FDA removed the cardiovascular black-box warning from testosterone product labels — a watershed moment for the field.

This regulatory shift has been particularly significant for men with type 2 diabetes and metabolic syndrome, who were previously the most likely to be denied TRT due to perceived cardiovascular risk. The science now supports what experienced clinicians at programs like Telehealth FX have long practiced: that appropriately monitored TRT is safe even in cardiovascularly complex patients. For a deeper dive into the TRAVERSE trial and cardiovascular safety, see our dedicated guide.

The T4DM Trial: Landmark Evidence for Diabetes Prevention

While TRAVERSE settled the safety question, the T4DM (Testosterone for the Prevention of Type 2 Diabetes Mellitus) trial provided some of the strongest evidence yet for the metabolic benefits of TRT.

Published by Wittert et al. in The Lancet Diabetes & Endocrinology in 2021, T4DM was a randomized, double-blind, placebo-controlled trial conducted across six Australian centers. Key details:

• Population: 1,007 men aged 50–74 with a waist circumference ≥95 cm, serum testosterone ≤14 nmol/L (≤403 ng/dL), and impaired glucose tolerance or newly diagnosed T2D on OGTT.
• Intervention: Testosterone undecanoate (1,000 mg IM) every 12 weeks for 2 years, alongside a lifestyle modification program. The control group received placebo injections plus the same lifestyle program.
• Primary outcome: Type 2 diabetes incidence at 2 years (diagnosed by OGTT).

T4DM Results

The results were striking:

• T2D developed in 12% of the testosterone group vs. 21% of the placebo group — a 41% relative risk reduction in diabetes onset (HR 0.59, 95% CI 0.43–0.80; p=0.0014).
• 2-hour glucose on OGTT improved by −0.95 mmol/L in the testosterone group versus −0.19 mmol/L in placebo.
• Fasting glucose was −0.26 mmol/L lower in the testosterone group.
• HbA1c decreased modestly but significantly more in the testosterone group.
• Visceral fat (measured by MRI) decreased significantly more in the testosterone group.
• Lean body mass increased by approximately 3.1 kg more in the testosterone group compared to placebo.

Critically, these benefits were additive to the lifestyle program — both groups received diet and exercise support. The testosterone group simply responded dramatically better. The T4DM investigators concluded that testosterone treatment "should be considered as an adjunct to lifestyle intervention" for at-risk men.

How TRT Improves Insulin Sensitivity: The Mechanisms

The metabolic benefits of TRT aren't just correlation — they operate through well-characterized molecular pathways:

1. Body Composition Remodeling

TRT consistently reduces visceral adipose tissue (VAT) while increasing lean mass. A 2016 meta-analysis by Corona et al. (Endocrine Reviews, 59 RCTs, n = 5,082) quantified the effects: TRT reduced body fat mass by an average of −1.6 kg and increased lean mass by +1.6 kg over treatment periods averaging 9 months. This body recomposition shifts the metabolic profile substantially — less visceral fat means less aromatase activity, less inflammatory cytokine production, and improved hepatic insulin sensitivity. This mirrors the body composition improvements seen across TRT populations.

2. Direct Insulin Receptor Sensitization

Testosterone directly enhances GLUT4 transporter expression in skeletal muscle cells, the primary mechanism by which glucose enters muscle tissue. Animal studies (Sato et al., 2008) demonstrated that androgen receptor activation upregulates GLUT4 mRNA by approximately 30% in skeletal muscle. In human studies, TRT has been shown to reduce HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) by 15–25% within 6–12 months of treatment initiation.

3. Anti-Inflammatory Effects

Chronic low-grade inflammation is a hallmark of both metabolic syndrome and hypogonadism. TRT reduces circulating levels of pro-inflammatory mediators. Malkin et al. (2004) demonstrated that testosterone replacement reduced TNF-α by 36% and IL-1β by 28% in hypogonadal men over 3 months. Since these cytokines directly impair insulin receptor substrate phosphorylation, their reduction translates to improved glucose handling.

4. Hepatic Glucose Output

Testosterone may also reduce hepatic glucose output. The TIMES2 trial (Jones et al., 2011; n = 220 hypogonadal men with T2D or metabolic syndrome) demonstrated that testosterone gel treatment for 12 months reduced HOMA-IR by 15.2% compared to placebo, with significant improvements in fasting glucose. This effect was partly attributed to reduced hepatic steatosis — testosterone helps clear intrahepatic fat, improving liver insulin sensitivity. For more on hormone therapy and fatty liver disease, see our GLP-1 and fatty liver guide.

The Case for Combined TRT + Weight Loss Therapy

The most powerful metabolic outcomes occur when TRT is combined with deliberate weight management. The T4DM trial demonstrated this: both groups received a lifestyle intervention, but the TRT group saw dramatically better metabolic results. The testosterone didn't just add a marginal benefit — it appeared to unlock the body's capacity to respond to lifestyle changes.

This makes biological sense. By restoring testosterone:

• Energy levels improve, making exercise feasible and sustainable
• Muscle protein synthesis increases, meaning resistance training produces better results
• Motivation and cognitive function improve, supporting dietary adherence
• Visceral fat begins to mobilize, reducing aromatase activity and further improving testosterone levels (a virtuous cycle)

For men with both hypogonadism and significant excess weight, combining TRT with a structured weight management program — potentially including GLP-1 therapy for metabolic syndrome — creates a synergistic effect that neither intervention achieves alone. This is exactly the kind of comprehensive, multi-pathway approach that modern telehealth programs are uniquely positioned to deliver.

Men over 50 with overlapping metabolic concerns may find our guide to GLP-1 therapy for men over 50 helpful for understanding how weight loss medications complement TRT protocols.

Additional Supporting Evidence: Registry and Long-Term Data

Beyond RCTs, real-world registry data has provided compelling long-term evidence:

• The Moscow Registry (Yassin et al., 2019): Followed 805 hypogonadal men with T2D receiving long-acting testosterone undecanoate for up to 12 years. Results showed sustained reductions in HbA1c (from 7.8% to 6.1%), fasting glucose, waist circumference (−11.8 cm), and body weight (−17.5 kg). Notably, 34.3% of men on testosterone achieved diabetes remission (HbA1c <6.5% without diabetes medications) — a remarkable finding.
• The IPASS Registry (Saad et al., 2016): An international prospective registry of 561 hypogonadal men treated with testosterone undecanoate for up to 8 years. Showed significant improvements in fasting glucose (−28.5 mg/dL), triglycerides (−50.4 mg/dL), and total cholesterol (−36.7 mg/dL) over the study period.
• Hackett et al. (2014): A UK study of 199 hypogonadal men with T2D treated with testosterone undecanoate for 30 weeks demonstrated a reduction in HbA1c of −0.41% (vs. +0.04% in the placebo group) and improvements in waist circumference, total cholesterol, and lipid profiles.

Safety Considerations for Diabetic Men on TRT

While the cardiovascular safety data from TRAVERSE is reassuring, men with type 2 diabetes and metabolic syndrome still require vigilant monitoring on TRT. Key considerations include:

Hematocrit Monitoring

Testosterone stimulates erythropoiesis. Diabetic men — especially those with obstructive sleep apnea, a common comorbidity — may be at increased baseline risk for polycythemia. Hematocrit should be checked at baseline, 3 months, 6 months, and every 6–12 months thereafter. Values exceeding 54% require dose reduction or therapeutic phlebotomy. For an in-depth guide to understanding this and other lab markers, see our complete TRT side effects guide.

Hypoglycemia Risk

This is a clinically important consideration that is frequently overlooked. As TRT improves insulin sensitivity, men on insulin or sulfonylureas may experience hypoglycemic episodes if their diabetes medications are not concurrently adjusted. HbA1c and fasting glucose should be monitored closely, particularly in the first 3–6 months, and diabetes medication doses should be proactively reduced as metabolic markers improve. Coordination between the prescribing TRT clinician and the patient's endocrinologist or primary care provider is essential.

Sleep Apnea Screening

Obstructive sleep apnea (OSA) is present in an estimated 60–80% of men with type 2 diabetes and obesity. Untreated OSA worsens both testosterone levels and glycemic control. TRT was historically thought to exacerbate sleep apnea, but the TRAVERSE trial found no significant increase in OSA severity with testosterone treatment. Nonetheless, screening for and treating OSA with CPAP therapy remains an important component of comprehensive metabolic care.

Cardiovascular Risk Management

While TRT itself does not increase cardiovascular events per TRAVERSE, men with T2D and metabolic syndrome have elevated baseline cardiovascular risk that must be managed independently. This includes appropriate statin therapy, blood pressure control, smoking cessation, and regular cardiovascular screening. TRT is an adjunct to comprehensive metabolic management, not a substitute for it.

Who Should Consider TRT + Metabolic Optimization?

Based on the current evidence, the strongest candidates for combined TRT and metabolic intervention are men who meet all of the following criteria:

1. Confirmed biochemical hypogonadism (morning Total T <300 ng/dL on two occasions, or Free T below age-adjusted optimal range)
2. Symptomatic presentation (fatigue, low libido, cognitive fog, loss of muscle mass, depressed mood)
3. Diagnosed type 2 diabetes, prediabetes, or metabolic syndrome (defined by ≥3 of: waist circumference >40 inches, triglycerides >150 mg/dL, HDL <40 mg/dL, blood pressure >130/85, fasting glucose >100 mg/dL)
4. Willing to engage in concurrent lifestyle modification (diet, exercise, weight management)
5. No absolute contraindications (active prostate cancer, polycythemia vera, severe untreated sleep apnea, desire for near-term fertility without adjunctive fertility preservation)

Frequently Asked Questions

Can TRT actually reverse type 2 diabetes?

In some cases, yes. Long-term registry data (Yassin et al., 2019) showed that 34.3% of hypogonadal men with T2D achieved diabetes remission after sustained testosterone treatment combined with lifestyle changes. However, "reversal" is more accurately described as long-term glycemic normalization — these men still need ongoing metabolic monitoring and healthy lifestyle maintenance.

Will I need to adjust my diabetes medications if I start TRT?

Potentially, yes. As insulin sensitivity improves, men on insulin, sulfonylureas, or other hypoglycemic agents may need dose reductions to avoid hypoglycemia. This should be coordinated between your TRT provider and your diabetes care team. At Telehealth FX, clinicians monitor metabolic markers closely and communicate findings that may affect concurrent medications.

Is TRT safe for men with heart disease and diabetes?

Yes, per the TRAVERSE trial data. TRAVERSE specifically enrolled men with pre-existing cardiovascular disease and found no increased risk of major cardiovascular events with testosterone treatment. The FDA removed the cardiovascular warning label in February 2025 based on this evidence.

Should I try weight loss first before starting TRT?

The evidence suggests that combining both simultaneously is more effective than either alone. Weight loss can partially restore testosterone levels (typically by 50–100 ng/dL per 10% body weight loss), but for men with clinically low testosterone, this improvement is often insufficient. The T4DM trial showed that TRT amplifies the metabolic benefits of lifestyle intervention. Starting both together creates a synergistic effect.

What's the best TRT protocol for metabolic optimization?

Most evidence supporting metabolic benefits comes from studies using testosterone undecanoate (long-acting IM injection) or testosterone gel. In clinical practice, testosterone cypionate injected subcutaneously or intramuscularly 2–3 times per week (to maintain stable levels and minimize estradiol conversion) is the most common protocol. The optimal dosage is individualized based on lab results and symptom response, typically 100–200 mg per week.